Exploring treatment options in cancer: Tumor treatment strategies – Nature.com

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca. Cancer J. Clin. 71, 209249 (2021).

Article PubMed Google Scholar

Worldwide cancer statistics. Cancer Research UK https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer (2015).

Frankel, R. I. Centennial of Rntgens discovery of x-rays. West. J. Med. 164, 497501 (1996).

CAS PubMed PubMed Central Google Scholar

Steinberg, F. M. & Raso, J. Biotech pharmaceuticals and biotherapy: an overview. J. Pharm. Pharm. Sci. 1, 4859 (1998).

CAS PubMed Google Scholar

Commissioner, O. of the. Drug Therapeutics & Regulation in the U.S. FDA https://www.fda.gov/about-fda/fda-history-exhibits/drug-therapeutics-regulation-us (2023).

Grillo-Lpez, A. J. et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol. 1, 19 (2000).

Article PubMed Google Scholar

Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101126 (2023).

Article CAS PubMed Google Scholar

Sun, X. et al. Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination. Cell Death Dis. 14, 839 (2023).

Article CAS PubMed PubMed Central Google Scholar

Sun, C., Gao, W., Liu, J., Cheng, H. & Hao, J. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir. Res. 21, 210 (2020).

Article CAS PubMed PubMed Central Google Scholar

Carter, J. & Tadi, P. Erlotinib. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2024).

Tewari, K. S. et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390, 16541663 (2017).

Article CAS PubMed PubMed Central Google Scholar

Hietanen, E., Koivu, M. K. A. & Susi, P. Cytolytic properties and genome analysis of Rigvir Oncolytic Virotherapy virus and other Echovirus 7 Isolates. Viruses 14, 525 (2022).

Article CAS PubMed PubMed Central Google Scholar

Sun, H. et al. TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC. Cell Death Dis. 13, 450 (2022).

Article CAS PubMed PubMed Central Google Scholar

Myers, R. M. et al. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T cells in CAR-Naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 39, 30443055 (2021).

Article CAS Google Scholar

Bouffet, Eric et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 11081120 (2023).

Article CAS PubMed Google Scholar

Carbone David, P. et al. First-line Nivolumab in Stage IV or recurrent nonsmall-cell lung cancer. N. Engl. J. Med. 376, 24152426 (2017).

Article CAS PubMed Google Scholar

Harrington, K. J. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the Phase III KEYNOTE-048 Study. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 41, 790802 (2023).

Article CAS Google Scholar

Joura Elmar, A. et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N. Engl. J. Med. 372, 711723 (2015).

Article CAS PubMed Google Scholar

Zhang, T. et al. Talimogene Laherparepvec (T-VEC): A review of the recent advances in cancer therapy. J. Clin. Med. 12, 1098 (2023).

Article CAS PubMed PubMed Central Google Scholar

Todo, T. et al. Intratumoral oncolytic herpes virus G47 for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 16301639 (2022).

Article CAS PubMed PubMed Central Google Scholar

Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 23712381 (2021).

Article CAS PubMed PubMed Central Google Scholar

Finn, R. S. et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 18941905 (2020).

Article CAS PubMed Google Scholar

Durante, M., Debus, J. & Loeffler, J. S. Physics and biomedical challenges of cancer therapy with accelerated heavy ions. Nat. Rev. Phys. 3, 777790 (2021).

Article CAS PubMed PubMed Central Google Scholar

Global Anti Tumor Drugs Market Research Report 2023. https://www.marketresearch.com/Bosson-Research-v4252/Global-Anti-Tumor-Drugs-Research-34934738/ (2023).

Falzone, L., Salomone, S. & Libra, M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018).

Article CAS PubMed PubMed Central Google Scholar

Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R. & Slusher, B. S. Clinical development of metabolic inhibitors for oncology. J. Clin. Invest. 132, e148550 (2022).

Article PubMed PubMed Central Google Scholar

Moreno, C., Muoz, C., Terol, M. J., Hernndez-Rivas, J.-. & Villanueva, M. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. J. Exp. Clin. Cancer Res. 40, 321 (2021).

Article CAS PubMed PubMed Central Google Scholar

Sliwoski, G., Kothiwale, S., Meiler, J. & Lowe, E. W. Computational methods in drug discovery. Pharmacol. Rev. 66, 334395 (2014).

Article PubMed PubMed Central Google Scholar

Benjin, X. & Ling, L. Developments, applications, and prospects of cryoelectron microscopy. Protein Sci. Publ. Protein Soc. 29, 872882 (2020).

Article Google Scholar

Tsukamoto, Y. et al. 150-kD oxygen-regulated protein is expressed in human atherosclerotic plaques and allows mononuclear phagocytes to withstand cellular stress on exposure to hypoxia and modified low density lipoprotein. J. Clin. Invest. 98, 19301941 (1996).

Article CAS PubMed PubMed Central Google Scholar

Hu, Y. et al. NMR-based methods for protein analysis. Anal. Chem. 93, 18661879 (2021).

Article CAS PubMed Google Scholar

Banerjee, A., Bhakta, S. & Sengupta, J. Integrative approaches in cryogenic electron microscopy: Recent advances in structural biology and future perspectives. iScience 24, 102044 (2021).

Article CAS PubMed PubMed Central Google Scholar

Dhakal, A., Gyawali, R., Wang, L. & Cheng, J. A large expert-curated cryo-EM image dataset for machine learning protein particle picking. Sci. Data 10, 392 (2023).

Article CAS PubMed PubMed Central Google Scholar

Skalidis, I. et al. Cryo-EM and artificial intelligence visualize endogenous protein community members. Struct. Lond. Engl. 30, 575589.e6 (2022).

CAS Google Scholar

Al-Azzawi, A., Ouadou, A., Tanner, J. J. & Cheng, J. AutoCryoPicker: An unsupervised learning approach for fully automated single particle picking in Cryo-EM images. BMC Bioinforma. 20, 326 (2019).

Article Google Scholar

Yu, H., Ma, H., Yang, K., Zhao, Y. & Jin, Y. DeepEM: Deep Neural Networks Model Recovery through EM Side-Channel Information Leakage. in 2020 IEEE International Symposium on Hardware Oriented Security and Trust (HOST) 209218 (2020). https://doi.org/10.1109/HOST45689.2020.9300274.

Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol. Res. 187, 106552 (2023).

Article CAS PubMed Google Scholar

Iqbal, N. & Iqbal, N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 19 (2014).

Article Google Scholar

Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517531 (2008).

Article CAS PubMed PubMed Central Google Scholar

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548551 (2013).

Article CAS PubMed PubMed Central Google Scholar

Jnne, P. A. et al. Adagrasib in NonSmall-Cell Lung Cancer Harboring a KRASG12C Mutation. N. Engl. J. Med. 387, 120131 (2022).

Article PubMed Google Scholar

Ferdinandos, S. et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 384, 23712381 (2021).

Araujo, L. H. et al. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. BMC Cancer 21, 193 (2021).

Article CAS PubMed PubMed Central Google Scholar

Qiu, J., Chen, K., Zhong, C., Zhu, S. & Ma, X. Network-based protein-protein interaction prediction method maps perturbations of cancer interactome. PLOS Genet. 17, e1009869 (2021).

Article CAS PubMed PubMed Central Google Scholar

Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the undruggable cancer targets. Nat. Rev. Cancer 17, 502508 (2017).

Article CAS PubMed PubMed Central Google Scholar

Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 23822393 (2021).

Article CAS PubMed PubMed Central Google Scholar

Hansen, A. L., Xiang, X., Yuan, C., Bruschweiler-Li, L. & Brschweiler, R. Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants. Nat. Struct. Mol. Biol. 30, 14461455 (2023).

Article CAS PubMed PubMed Central Google Scholar

Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J. & Haigis, K. M. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun. 12, 1808 (2021).

Article CAS PubMed PubMed Central Google Scholar

Lavoie, H., Gagnon, J. & Therrien, M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat. Rev. Mol. Cell Biol. 21, 607632 (2020).

Article CAS PubMed Google Scholar

Research, C. for D. E. and. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc (2021).

Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160166 (2023).

Article CAS PubMed PubMed Central Google Scholar

Changeux, J.-P. & Christopoulos, A. Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166, 10841102 (2016).

Article CAS PubMed Google Scholar

Hughes Timothy, P. et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase inhibitor failure. N. Engl. J. Med. 381, 23152326 (2019).

Article CAS PubMed Google Scholar

Larkin, J. et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N. Engl. J. Med. 371, 18671876 (2014).

Originally posted here:
Exploring treatment options in cancer: Tumor treatment strategies - Nature.com